UK 09:11 Sunday, 27 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Premaitha Health (NIPT) has announced results for its half year ended 30th September 2015, that “we have a good pipeline of prospects and we are confident that we will continue to build our revenues throughout the forthcoming period” and an up to £5 million loan facility from $17 billion revenue science company Thermo Fisher.
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Comments
wildrides
Naah …………. its a sell until the Patent Infringement Court Case , at the High Court . After that ……… well , wait and see .
Blimey , some of these HSR tips are really starting to crater now . First Teathers and now Mira down 70%
John Smith
BOD have stated 5 more contracts before end of March 16.
The £5M deal with US life sciences giant Thermo Fisher is very significant here (could be gearing up to launch a take-over) and shows a massive vote of confidence in Premaitha.
TF and those signing new contracts are clearly not concerned with the litigation, Premaitha have a strong defence and will walk it …
The basis of the Illumina writ against Premaitha is that they are claiming patent ownership of a ‘naturally occurring substance’. The courts in USA have thrown out the claim twice recently (latest one below) and the same will be repeated here.
Premaitha’s defence is that the IONA test is a ‘method’ which is different to Illumina’s hence no infringement.
US | Wed Dec 2, 2015 4:53pm EST
Related: U.S., Health
U.S. court rejects Sequenom bid to restore prenatal DNA test patent
A U.S. appeals court refused on Wednesday to reconsider its decision invalidating a Sequenom Inc prenatal DNA test patent, a decision that could put in doubt the validity of a wide range of medical and biotechnology patents.
The U.S. Court of Appeals for the Federal Circuit in Washington said in June the patent was not eligible for legal protection because it fell under the U.S. Supreme Court’s rule against patenting natural phenomena. That decision upheld a ruling by a lower federal court in California that cleared Roche Holding AG unit Ariosa Diagnostics of infringement.
wildrides
What ever ……………the shares will still crater before the court case …………. then you can buy them cheap . If its just a method then anyone can do it and then I cant see NIPT ever making a profit from doing it .